Micro-X Limited (MCRXF) Fair Value & Analysis
Healthcare · US · Market cap $21.9M
Fair value as of: Jun 26, 2026
Analysis
Micro-X Limited (MCRXF) currently trades at $0.0300, while our model-based Fair Value estimate is $0.0240 — implying the stock looks roughly 20.0% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Micro-X Limited designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components. It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; Argus, a wide-area scattered projection backscatter and miniaturized high-voltage generator; and space imaging solutions. The company operates in Australia, the United States, the Asia-Pacific, Europe, the Middle East, and Africa. Micro-X Limited was incorporated in 2011 and is based in Tonsley, Australia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Micro-X Limited (MCRXF) undervalued?
What is the fair value of MCRXF?
What is the quality score of MCRXF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.